PTC Therapeutics

Spinal muscular atrophy program enters phase Ib/IIa trial in patients with SMA

Thursday, November 20, 2014 01:19 PM

PTC Therapeutics’ joint development program in spinal muscular atrophy (SMA) with Roche and the SMA Foundation (SMAF) has started a phase Ib/IIa study in adult and pediatric patients. The placebo-controlled, randomized, multiple-dose study will enroll approximately 48 patients with SMA and investigate the safety and tolerability of an investigational survival of motor neuron 2 (SMN2) gene splicing modifier (RG7800) over 12 weeks. The achievement of this milestone triggers a $10 million payment to PTC from Roche.

More... »


PTC Therapeutics expands management team

Monday, January 27, 2014 02:47 PM

PTC Therapeutics has expanded its senior management team with the appointment of Robert J. Spiegel, M.D., FACP, to chief medical officer and Murad Husain to vice president, Global Regulatory Affairs. PTC also announced the promotions of Joseph Colacino, Ph.D., to senior vice president, Drug Discovery and Ernest R. Dietel to senior vice president, Quality. In addition, Jay Barth, M.D., senior vice president of Clinical Development, is leaving PTC to pursue other opportunities.

More... »


PTC Therapeutics, the SMA Foundation and Roche collaborate

Friday, January 24, 2014 10:39 AM

PTC Therapeutics, the SMA Foundation and Roche have announced that their joint research program in Spinal Muscular Atrophy (SMA) has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy volunteers. SMA is a genetic neuromuscular disorder that leads to muscle weakness and mobility impairment and is considered the leading genetic cause of death in infants and toddlers.

More... »

PTC Therapeutics announces milestone in SMA collaboration

Tuesday, August 13, 2013 10:00 AM

PTC Therapeutics has announced the selection of a development candidate in its spinal muscular atrophy (SMA) collaboration with Roche and the SMA Foundation. The achievement of the milestone triggers a $10 million payment to PTC from Roche.

More... »

PTC Therapeutics appoints Zeldis to board of directors

Thursday, October 4, 2012 12:14 PM

PTC Therapeutics, a biopharmaceutical company based in South Plainfield, N.J., has appointed Jerome B. Zeldis, M.D., Ph.D., to the company's board of directors.

More... »

PTC Therapeutics raises $30M for ataluren in muscular dystrophy

Monday, July 23, 2012 12:36 PM

PTC Therapeutics, a biopharmaceutical company based in South Plainfield, N.J., has completed a $30 million round of financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S and other existing investors.

More... »

PTC Therapeutics receives $5 million award from the Wellcome Trust

Friday, December 23, 2011 10:45 AM

PTC Therapeutics has received a $5 million Seeding Drug Discovery (SDD) award from the Wellcome Trust to support the development of small-molecule drugs that target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative bacteria. PTC previously received a $5.4 million SDD Award from the Wellcome Trust to support its BMI1 oncology program.

More... »

Roche, PTC sign potential $490m licensing deal

Tuesday, November 29, 2011 01:56 PM

Roche, PTC Therapeutics, and the SMA Foundation, have signed a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) program. SMA is a genetic neuromuscular disorder that causes muscle weakness.

More... »

AstraZeneca, PTC collaborate in oncology

Thursday, June 30, 2011 09:59 AM

AstraZeneca and PTC Therapeutics are joining forces for cancer cures, using PTC's discovery/development technology platform, reported FierceBiotech.  AZ will front an undisclosed amount of cash to work on the first oncology target.

More... »

Stay Granted in Muscular Dystrophy Clinical Trial Case

Friday, September 19, 2008 12:38 PM

The U.S. Court of Appeals for the Third Circuit has granted PTC Therapeutics’ request for a stay of the Federal District Court’s decision on August 20 that would have forced the biotech company to provide its experimental drug PTC124 to 16-year-old Duchenne muscular dystrophy patient Jacob Gunvalson outside its clinical trial process.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs